Abstract: Disclosed herein are methods for treating a cancer comprising administering to a subject in need thereof an effective dose of a CYP26-resistant retinoic acid receptor (RAR) alpha (RAR?) selective agonist, whereby as a result of the treatment the tumor burden is reduced in the subject and cancer stem cells resident in the bone marrow are substantially reduced.
Type:
Grant
Filed:
December 29, 2020
Date of Patent:
May 16, 2023
Assignees:
IO Therapeutics, Inc., The Johns Hopkins Univercity
Inventors:
Gabriel Ghiaur, Richard J. Jones, Salvador Alonso, Roshantha A. Chandraratna